BRF
EVOK

B. Riley Financial’s Evoke Pharma EVOK Stock Holding History

B. Riley Financial’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,000
Closed -$12.2K – 42
2025
Q1 		$12.2K Buy
+20,000
New +$84.9K 0.02% 23
2018
Q1 		– Sell
-764
Closed -$249K – 305
2017
Q4 		$249K Buy
+764
New +$317K 0.07% 252

Other funds holding EVOK

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

B. Riley Financial's EVOK Position: Q2 2025 in Review

B. Riley Financial sold out of Evoke Pharma (EVOK) in Q2 2025, closing a stake of 20,000 shares — an estimated $12.2K sold.

B. Riley Financial first reported a position in EVOK in Q4 2017 and held it in 2 quarters. The position peaked at $249K in Q4 2017. 10 funds tracked by Wall St. Rank hold EVOK as of Q2 2025.

  • B. Riley Financial reported no remaining Evoke Pharma position as of Q2 2025 after selling out during the quarter.
  • B. Riley Financial sold 20,000 Evoke Pharma shares in Q2 2025, an estimated $12.2K.
  • B. Riley Financial first reported a position in Evoke Pharma in Q4 2017 and held it in 2 quarters.
  • B. Riley Financial's Evoke Pharma position peaked at $249K in Q4 2017.
  • 10 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2025.

Based on B. Riley Financial's 13F filing for Q2 2025, filed 3 Feb 2026.